lOMoAR cPSD| 21007614
Pharmacotherapeutics nfor nAdvanced nPractice- nA
nPracticaln
Approach n5th nEdition nArcangelo nTest nBank
Pharmacology nfor nAdvanced nPractice nNursing n(Kennesaw nState nUniversity)
Studocu nis nnot nsponsored nor nendorsed nby nany ncollege nor nuniversity
Downloaded nby nPatrick nLiquete
, lOMoAR cPSD| 21007614
Chapter n1 nIssues nfor nthe nPractitioner nin nDrug nTherapy
MULTIPLE nCHOICE
1. Nurse npractitioner nprescriptive nauthority nis nregulated nby:
A. The nNational nCouncil nof nState nBoards nof nNursing
B. The nU.S. nDrug nEnforcement nAdministration
C. The nState nBoard nof nNursing nfor neach nstate
D. The nState nBoard nof nPharmacy
ANS: n C PTS: n 1
2. Physician nAssistant n(PA) nprescriptive nauthority nis nregulated nby:
A. The nNational nCouncil nof nState nBoards nof nNursing
B. The nU.S. nDrug nEnforcement nAdministration
C. The nState nBoard nof nNursing
D. The nState nBoard nof nMedical nExaminers
ANS: n D PTS: n 1
3. Clinical njudgment nin nprescribing nincludes:
A. Factoring nin nthe ncost nto nthe npatient nof nthe nmedication nprescribed
B. Always nprescribing nthe nnewest nmedication navailable nfor nthe ndisease nprocess
C. Handing nout ndrug nsamples nto npoor npatients
D. Prescribing nall ngeneric nmedications nto ncut ncosts
ANS: n A PTS: n 1
4. Criteria nfor nchoosing nan neffective ndrug nfor na ndisorder ninclude:
A. Asking nthe npatient nwhat ndrug nthey nthink nwould nwork nbest nfor nthem
B. Consulting nnationally nrecognized nguidelines nfor ndisease nmanagement
C. Prescribing nmedications nthat nare navailable nas nsamples nbefore nwriting na nprescription
D. Following nU.S. nDrug nEnforcement nAdministration n(DEA)
nguidelines nfornprescribing
ANS: n B PTS: n 1
5. Nurse npractitioner npractice nmay nthrive nunder nhealth-care nreform ndue nto:
A. The ndemonstrated nability nof nnurse npractitioners nto ncontrol ncosts nand nimprove
npatientnoutcomes
B. The nfact nthat nnurse npractitioners nwill nbe nable nto npractice nindependently
C. The nfact nthat nnurse npractitioners nwill nhave nfull nreimbursement nunder
nhealth-carenreform
D. The nability nto nshift naccountability nfor nMedicaid nto nthe nstate nlevel
ANS: n A PTS: n 1
WWW.TEGTBANKTANK.COM
Downloaded nby nPatrick nLiquete
n()
, lOMoAR cPSD| 21007614
Chapter n2.Pharmacokinetic nBasis nof nTherapeutics nand nPharmacodynamic
MULTIPLE nCHOICE
1. A npatient's nnutritional nintake nand nlab nwork nreflects nhypoalbuminemia. nThis nis
ncritical ntonprescribing nbecause:
A. Distribution nof ndrugs nto ntarget ntissue nmay nbe naffected
B. The nsolubility nof nthe ndrug nwill nnot nmatch nthe nsite nof nabsorption
C. There nwill nbe nless nfree ndrug navailable nto ngenerate nan neffect
D. Drugs nbound nto nalbumin nare nreadily nexcreted nby nthe nkidney
ANS: n A PTS: n 1
2. Drugs nthat nhave na nsignificant nfirst-pass neffect:
A. Must nbe ngiven nby nthe nenteral n(oral) nroute nonly
B. Bypass nthe nhepatic ncirculation
C. Are nrapidly nmetabolized nby nthe nliver nand nmay nhave nlittle nif nany ndesired naction
D. Are nconverted nby nthe nliver nto nmore nactive nand nfat-soluble nforms
ANS: n C PTS: n 1
3. The nroute nof nexcretion nof na nvolatile ndrug nwill nlikely nbe:
A. The nkidneys
B. The nlungs
C. The nbile nand nfeces
D. The nskin
ANS: n B PTS: n 1
4. Medroxyprogesterone n(Depo nProvera) nis nprescribed nIM nto ncreate na nstorage nreservoir
nof nthendrug. nStorage nreservoirs:
A. Assure nthat nthe ndrug nwill nreach nits nintended ntarget ntissue
B. Are nthe nreason nfor ngiving nloading ndoses
C. Increase nthe nlength nof ntime na ndrug nis navailable nand nactive
D. Are nmost ncommon nin ncollagen ntissues
ANS: n C PTS: n 1
5. The nNP nchooses nto ngive ncephalexin nevery n8 nhours nbased non nknowledge nof nthe ndrug's:
A. Propensity nto ngo nto nthe ntarget nreceptor
B. Biological nhalf-life
C. Pharmacodynamics
D. Safety nand nside neffects
ANS: n B PTS: n 1
6. Azithromycin ndosing nrequires nthe nfirst nday's ndose nbe ntwice nthose nof nthe nother n4
ndays nof nthenprescription. nThis nis nconsidered na nloading ndose. nA nloading ndose:
A. Rapidly nachieves ndrug nlevels nin nthe ntherapeutic nrange
B. Requires nfour nto nfive nhalf-lives nto nattain
C. Is ninfluenced nby nrenal nfunction
WWW.TEGTBANKTANK.COM
Downloaded nby nPatrick nLiquete
n()
, lOMoAR cPSD| 21007614
D. Is ndirectly nrelated nto nthe ndrug ncirculating nto nthe ntarget ntissues
ANS: n A PTS: n n n 1
7. The npoint nin ntime non nthe ndrug nconcentration ncurve nthat nindicates nthe nfirst nsign nof na
ntherapeuticneffect nis nthe:
A. Minimum nadverse neffect nlevel
B. Peak nof naction
C. Onset nof naction
D. Therapeutic nrange
ANS: n C PTS: n 1
8. Phenytoin nrequires na ntrough nlevel nbe ndrawn. nPeak nand ntrough nlevels nare ndone:
A. When nthe ndrug nhas na nwide ntherapeutic nrange
B. When nthe ndrug nwill nbe nadministered nfor na nshort ntime nonly
C. When nthere nis na nhigh ncorrelation nbetween nthe ndose nand nsaturation nof nreceptor nsites
D. To ndetermine nif na ndrug nis nin nthe ntherapeutic nrange
ANS: n D PTS: n 1
9. A nlaboratory nresult nindicates nthe npeak nlevel nfor na ndrug nis nabove nthe
nminimum ntoxicnconcentration. nThis nmeans nthat nthe:
A. Concentration nwill nproduce ntherapeutic neffects
B. Concentration nwill nproduce nan nadverse nresponse
C. Time nbetween ndoses nmust nbe nshortened
D. Duration nof naction nof nthe ndrug nis ntoo nlong
ANS: n B PTS: n 1
10. Drugs nthat nare nreceptor nagonists nmay ndemonstrate nwhat nproperty?
A. Irreversible nbinding nto nthe ndrug nreceptor nsite
B. Up-regulation nwith nchronic nuse
C. Desensitization nor ndown-regulation nwith ncontinuous nuse
D. Inverse nrelationship nbetween ndrug nconcentration nand ndrug naction
ANS: n C PTS: n 1
11. Drugs nthat nare nreceptor nantagonists, nsuch nas nbeta nblockers, nmay ncause:
A. Down-regulation nof nthe ndrug nreceptor
B. An nexaggerated nresponse nif nabruptly ndiscontinued
C. Partial nblockade nof nthe neffects nof nagonist ndrugs
D. An nexaggerated nresponse nto ncompetitive ndrug nagonists
ANS: n B PTS: n 1
12. Factors nthat naffect ngastric ndrug nabsorption ninclude:
A. Liver nenzyme nactivity
B. Protein-binding nproperties nof nthe ndrug nmolecule
C. Lipid nsolubility nof nthe ndrug
D. Ability nto nchew nand nswallow
ANS: n C PTS: n 1
WWW.TEGTBANKTANK.COM
Downloaded nby nPatrick nLiquete
n()
Pharmacotherapeutics nfor nAdvanced nPractice- nA
nPracticaln
Approach n5th nEdition nArcangelo nTest nBank
Pharmacology nfor nAdvanced nPractice nNursing n(Kennesaw nState nUniversity)
Studocu nis nnot nsponsored nor nendorsed nby nany ncollege nor nuniversity
Downloaded nby nPatrick nLiquete
, lOMoAR cPSD| 21007614
Chapter n1 nIssues nfor nthe nPractitioner nin nDrug nTherapy
MULTIPLE nCHOICE
1. Nurse npractitioner nprescriptive nauthority nis nregulated nby:
A. The nNational nCouncil nof nState nBoards nof nNursing
B. The nU.S. nDrug nEnforcement nAdministration
C. The nState nBoard nof nNursing nfor neach nstate
D. The nState nBoard nof nPharmacy
ANS: n C PTS: n 1
2. Physician nAssistant n(PA) nprescriptive nauthority nis nregulated nby:
A. The nNational nCouncil nof nState nBoards nof nNursing
B. The nU.S. nDrug nEnforcement nAdministration
C. The nState nBoard nof nNursing
D. The nState nBoard nof nMedical nExaminers
ANS: n D PTS: n 1
3. Clinical njudgment nin nprescribing nincludes:
A. Factoring nin nthe ncost nto nthe npatient nof nthe nmedication nprescribed
B. Always nprescribing nthe nnewest nmedication navailable nfor nthe ndisease nprocess
C. Handing nout ndrug nsamples nto npoor npatients
D. Prescribing nall ngeneric nmedications nto ncut ncosts
ANS: n A PTS: n 1
4. Criteria nfor nchoosing nan neffective ndrug nfor na ndisorder ninclude:
A. Asking nthe npatient nwhat ndrug nthey nthink nwould nwork nbest nfor nthem
B. Consulting nnationally nrecognized nguidelines nfor ndisease nmanagement
C. Prescribing nmedications nthat nare navailable nas nsamples nbefore nwriting na nprescription
D. Following nU.S. nDrug nEnforcement nAdministration n(DEA)
nguidelines nfornprescribing
ANS: n B PTS: n 1
5. Nurse npractitioner npractice nmay nthrive nunder nhealth-care nreform ndue nto:
A. The ndemonstrated nability nof nnurse npractitioners nto ncontrol ncosts nand nimprove
npatientnoutcomes
B. The nfact nthat nnurse npractitioners nwill nbe nable nto npractice nindependently
C. The nfact nthat nnurse npractitioners nwill nhave nfull nreimbursement nunder
nhealth-carenreform
D. The nability nto nshift naccountability nfor nMedicaid nto nthe nstate nlevel
ANS: n A PTS: n 1
WWW.TEGTBANKTANK.COM
Downloaded nby nPatrick nLiquete
n()
, lOMoAR cPSD| 21007614
Chapter n2.Pharmacokinetic nBasis nof nTherapeutics nand nPharmacodynamic
MULTIPLE nCHOICE
1. A npatient's nnutritional nintake nand nlab nwork nreflects nhypoalbuminemia. nThis nis
ncritical ntonprescribing nbecause:
A. Distribution nof ndrugs nto ntarget ntissue nmay nbe naffected
B. The nsolubility nof nthe ndrug nwill nnot nmatch nthe nsite nof nabsorption
C. There nwill nbe nless nfree ndrug navailable nto ngenerate nan neffect
D. Drugs nbound nto nalbumin nare nreadily nexcreted nby nthe nkidney
ANS: n A PTS: n 1
2. Drugs nthat nhave na nsignificant nfirst-pass neffect:
A. Must nbe ngiven nby nthe nenteral n(oral) nroute nonly
B. Bypass nthe nhepatic ncirculation
C. Are nrapidly nmetabolized nby nthe nliver nand nmay nhave nlittle nif nany ndesired naction
D. Are nconverted nby nthe nliver nto nmore nactive nand nfat-soluble nforms
ANS: n C PTS: n 1
3. The nroute nof nexcretion nof na nvolatile ndrug nwill nlikely nbe:
A. The nkidneys
B. The nlungs
C. The nbile nand nfeces
D. The nskin
ANS: n B PTS: n 1
4. Medroxyprogesterone n(Depo nProvera) nis nprescribed nIM nto ncreate na nstorage nreservoir
nof nthendrug. nStorage nreservoirs:
A. Assure nthat nthe ndrug nwill nreach nits nintended ntarget ntissue
B. Are nthe nreason nfor ngiving nloading ndoses
C. Increase nthe nlength nof ntime na ndrug nis navailable nand nactive
D. Are nmost ncommon nin ncollagen ntissues
ANS: n C PTS: n 1
5. The nNP nchooses nto ngive ncephalexin nevery n8 nhours nbased non nknowledge nof nthe ndrug's:
A. Propensity nto ngo nto nthe ntarget nreceptor
B. Biological nhalf-life
C. Pharmacodynamics
D. Safety nand nside neffects
ANS: n B PTS: n 1
6. Azithromycin ndosing nrequires nthe nfirst nday's ndose nbe ntwice nthose nof nthe nother n4
ndays nof nthenprescription. nThis nis nconsidered na nloading ndose. nA nloading ndose:
A. Rapidly nachieves ndrug nlevels nin nthe ntherapeutic nrange
B. Requires nfour nto nfive nhalf-lives nto nattain
C. Is ninfluenced nby nrenal nfunction
WWW.TEGTBANKTANK.COM
Downloaded nby nPatrick nLiquete
n()
, lOMoAR cPSD| 21007614
D. Is ndirectly nrelated nto nthe ndrug ncirculating nto nthe ntarget ntissues
ANS: n A PTS: n n n 1
7. The npoint nin ntime non nthe ndrug nconcentration ncurve nthat nindicates nthe nfirst nsign nof na
ntherapeuticneffect nis nthe:
A. Minimum nadverse neffect nlevel
B. Peak nof naction
C. Onset nof naction
D. Therapeutic nrange
ANS: n C PTS: n 1
8. Phenytoin nrequires na ntrough nlevel nbe ndrawn. nPeak nand ntrough nlevels nare ndone:
A. When nthe ndrug nhas na nwide ntherapeutic nrange
B. When nthe ndrug nwill nbe nadministered nfor na nshort ntime nonly
C. When nthere nis na nhigh ncorrelation nbetween nthe ndose nand nsaturation nof nreceptor nsites
D. To ndetermine nif na ndrug nis nin nthe ntherapeutic nrange
ANS: n D PTS: n 1
9. A nlaboratory nresult nindicates nthe npeak nlevel nfor na ndrug nis nabove nthe
nminimum ntoxicnconcentration. nThis nmeans nthat nthe:
A. Concentration nwill nproduce ntherapeutic neffects
B. Concentration nwill nproduce nan nadverse nresponse
C. Time nbetween ndoses nmust nbe nshortened
D. Duration nof naction nof nthe ndrug nis ntoo nlong
ANS: n B PTS: n 1
10. Drugs nthat nare nreceptor nagonists nmay ndemonstrate nwhat nproperty?
A. Irreversible nbinding nto nthe ndrug nreceptor nsite
B. Up-regulation nwith nchronic nuse
C. Desensitization nor ndown-regulation nwith ncontinuous nuse
D. Inverse nrelationship nbetween ndrug nconcentration nand ndrug naction
ANS: n C PTS: n 1
11. Drugs nthat nare nreceptor nantagonists, nsuch nas nbeta nblockers, nmay ncause:
A. Down-regulation nof nthe ndrug nreceptor
B. An nexaggerated nresponse nif nabruptly ndiscontinued
C. Partial nblockade nof nthe neffects nof nagonist ndrugs
D. An nexaggerated nresponse nto ncompetitive ndrug nagonists
ANS: n B PTS: n 1
12. Factors nthat naffect ngastric ndrug nabsorption ninclude:
A. Liver nenzyme nactivity
B. Protein-binding nproperties nof nthe ndrug nmolecule
C. Lipid nsolubility nof nthe ndrug
D. Ability nto nchew nand nswallow
ANS: n C PTS: n 1
WWW.TEGTBANKTANK.COM
Downloaded nby nPatrick nLiquete
n()
